Lepu Biopharma Co., Ltd. (02157.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 4.02

From 52W high−51.95%

Volume8.49M

Market capHKD 7.13B

P/E (TTM)25.7x

P/S (TTM)6.2x

Div yield—

Key dataSep 18, 2026

Open

HKD 4.02

From 52W high

−51.95%

Volume

8.49M

Market cap

HKD 7.13B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

56.9x

P/E (TTM)

25.7x

RSI (14)

47.2

MomentumView details →

1D Return

+3.44%

YTD Return

−18.31%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

25.7x

EV/EBITDA

56.9x

EV/Sales

6.6x

P/S (TTM)

6.2x

P/B (TTM)

4.3x

ProfitabilityView details →

Gross Margin

79.09%

Net Margin

24.89%

EBITDA Margin

11.62%

ROE (TTM)

17.20%

ROA (TTM)

7.68%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

+39.38%

EPS YoY

+225.00%

FCF YoY

+18.24%

Revenue CAGR 3Y

+288.16%

EPS CAGR 3Y

+158.33%

EBITDA YoY

+256.76%

MomentumView details →

1D Return

+3.44%

YTD Return

−18.31%

1Y Return

−46.93%

RSI (14)

47.2

vs 50D SMA

−6.18%

vs 200D SMA

−14.94%

Capital & dividendView details →

Debt/Equity

0.84x

Current Ratio

1.14x

Quick Ratio

1.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.02

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.68B

Net Income (TTM)

65.77M

Op. CF (TTM)

—

Next earningsMar 31, 2027 →

Latest newsMore news →

Lepu Biopharma announced its interim results for the six months ended June 2026, with revenue of RMB 522 million, up 12.1% year-on-year, and net profit of RMB 27.39 million, down 34.4% year-on-year.32d ago

Similar companies

诺禾致源688315.SH 星湖科技600866.SH Alkermes plcALKS CARsgen Therapeutics Holdings Limited02171.HK Belite Bio, IncBLTE Ionis Pharmaceuticals, Inc.IONS Find similar companies →

Latest newsMore news →

Lepu Biopharma announced its interim results for the six months ended June 2026, with revenue of RMB 522 million, up 12.1% year-on-year, and net profit of RMB 27.39 million, down 34.4% year-on-year.32d ago